SeaStar Medical Holding Corp (ICU) shareholders
Close on Nov 17, 2026Market cap $3.44MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Mitchell P. Kopin Joint filing with Daniel B. Asher (9.99%), Intracoastal Capital LLC (9.99%) | 3,098,175 | 9.99% | 13G (passive) amendment | Sep 30, 2025 |
| Armistice Capital, LLC Joint filing with Steven Boyd (9.99%) | 1,019,958 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Intracoastal Capital LLC Joint filing with Mitchell P. Kopin (9.99%), Daniel B. Asher (9.99%) | 489,105 | 9.99% | 13G (passive) amendment | Sep 30, 2026 |
| Daniel B. Asher Joint filing with Mitchell P. Kopin (9.99%), Intracoastal Capital LLC (9.99%) | 443,253 | 9.99% | 13G (passive) amendment | Mar 31, 2026 |
| Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B Joint filing with Ayrton Capital LLC (6.52%), Waqas Khatri (6.52%) | 278,436 | 6.52% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ICU | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Geode Capital Management, LLC | 49,593 | – | $182.01K | −6,049 | 0.00% |
| Vanguard Capital Management LLC | 33,091 | – | $121.44K | +4,300 | 0.00% |
| UBS Group AG | 31,398 | – | $115.23K | +30,605 | 0.00% |
| Vanguard Fiduciary Trust Co | 13,692 | – | $50.25K | – | 0.00% |
| Jane Street Group, LLC | 12,634 | – | $46.37K | −15,326 | 0.00% |
| Northern Trust Corp | 10,402 | – | $38.18K | New | 0.00% |
| PNC Financial Services Group, Inc. | 4,943 | – | $18.14K | +3,195 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,356 | – | $4.98K | −39 | 0.00% |
| BlackRock, Inc. | 913 | – | $3.35K | – | 0.00% |
| Osaic Holdings, Inc. | 195 | – | $714 | −35 | 0.00% |
| NewEdge Advisors, LLC | 176 | – | $647 | – | 0.00% |
| Vanguard Global Advisers, LLC | 165 | – | $606 | – | 0.00% |
| TD Waterhouse Canada Inc. | 22 | – | $106 | – | 0.00% |
| SBI Securities Co., Ltd. | 14 | – | $51 | – | 0.00% |
| SOA Wealth Advisors, LLC. | 6 | – | $22 | – | 0.00% |
| Barclays PLC | 4 | – | $15 | New | 0.00% |
| HighMark Wealth Management LLC | 2 | – | $7 | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 2 | – | $7 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 18 | 0M | 3 / 3 | 4 / 1 | 0M | 0M |
| Q1 2026 | 17 | 0M | 15 / 0 | 1 / 0 | 0M | 0M |
| Q4 2025 | 2 | 0M | 2 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
6 funds held ICU in Q2 2026, 48% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ICU | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 33,091 | – | $121.44K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 21,929 | – | $81.36K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 8,656 | – | $32.11K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 5,814 | – | $21.57K | 0.00% | May 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 2,835 | – | $8.87K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 447 | – | $1.66K | 0.00% | May 31, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -700 | – | -$2.57K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michael Messinger | Chief Financial Officer | 5,000 | Nov 17, 2026 |
| Kevin Chung | Chief Medical Officer | 35,821 | Nov 17, 2026 |
| Eric Schlorff | Chief Executive Officer | 50,140 | Jul 2, 2026 |
| Bradford K. Towne | Principal Accounting Officer | 9,050 | Feb 10, 2026 |
| David A. Green | Chief Financial Officer | 10,323 | Apr 3, 2025 |
| Heel Kenneth Van | Director | 11,940 | Jul 2, 2026 |
| Bernadette N. Vincent | Director | 8,200 | Jul 2, 2026 |
| Jennifer A. Baird | Director | 10,620 | Jul 2, 2026 |
| John Neuman | Director | 16,200 | Jul 2, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Messinger Chief Financial Officer | Nov 16, 2026 | Buy | +2,500 | $0.85 | $2.12K | 5,000 |
| Kevin Chung Chief Medical Officer | Nov 16, 2026 | Buy | +7,800 | $0.84 | $6.59K | 35,821 |
| Michael Messinger Chief Financial Officer | Aug 18, 2026 | Buy | +750 | $3.27 | $2.45K | 2,500 |
| John Neuman Director | Jul 1, 2026 | Award | +4,000 | – | – | 16,200 |
| Jennifer A. Baird Director | Jul 1, 2026 | Award | +4,000 | – | – | 10,620 |
| Eric Schlorff Chief Executive Officer | Jul 1, 2026 | Award | +10,288 | – | – | 50,140 |
| Heel Kenneth Van Director | Jul 1, 2026 | Award | +4,000 | – | – | 11,940 |
| Bernadette N. Vincent Director | Jul 1, 2026 | Award | +4,000 | – | – | 8,200 |
| Kevin Chung Chief Medical Officer | Jul 1, 2026 | Award | +7,202 | – | – | 28,021 |
| Jennifer A. Baird Director | Feb 6, 2026 | Award | +3,000 | – | – | 6,620 |
| Eric Schlorff Chief Executive Officer | Feb 6, 2026 | Award | +30,000 | – | – | 39,852 |
| Bradford K. Towne Principal Accounting Officer | Feb 6, 2026 | Award | +7,500 | – | – | 9,050 |
| Kevin Chung Chief Medical Officer | Feb 6, 2026 | Award | +15,000 | – | – | 20,819 |
| John Neuman Director | Feb 6, 2026 | Award | +3,000 | – | – | 12,200 |
| Bernadette N. Vincent Director | Feb 6, 2026 | Award | +3,000 | – | – | 4,200 |
| Heel Kenneth Van Director | Feb 6, 2026 | Award | +3,000 | – | – | 7,940 |
| Jennifer A. Baird Director | Dec 19, 2025 | Buy | +4,200 | $0.24 | $1.01K | 36,200 |
| Michael Messinger Chief Financial Officer | Dec 9, 2025 | Buy | +14,500 | $0.35 | $5.08K | 17,500 |
| Heel Kenneth Van Director | Aug 27, 2025 | Buy | +10,000 | $0.86 | $8.60K | 49,400 |
| Heel Kenneth Van Director | Aug 26, 2025 | Buy | +25,000 | $0.89 | $22.25K | 39,400 |
| Kevin Chung Chief Medical Officer | Aug 22, 2025 | Buy | +10,000 | $0.80 | $8.00K | 58,184 |
| Bernadette N. Vincent Director | Jul 10, 2025 | Award | +4,000 | – | – | 12,000 |
| Heel Kenneth Van Director | Jul 10, 2025 | Award | +4,000 | – | – | 14,400 |
| John Neuman Director | Jul 10, 2025 | Award | +4,000 | – | – | 92,000 |
| Jennifer A. Baird Director | Jul 10, 2025 | Award | +4,000 | – | – | 32,000 |
| Eric Schlorff Chief Executive Officer, Director | Jul 1, 2025 | Option exercise | +21,667 | – | – | 98,517 |
| Kevin Chung Chief Medical Officer | Jul 1, 2025 | Option exercise | +5,000 | – | – | 48,184 |
| Jennifer A. Baird Director | Jun 30, 2025 | Buy | +10,000 | $0.42 | $4.20K | 28,000 |
| John Neuman Director | Jun 24, 2025 | Buy | +40,000 | $0.36 | $14.40K | 80,000 |
| Bernadette N. Vincent Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 8,000 |
| Heel Kenneth Van Director | Jun 4, 2025 | Option exercise | +4,000 | – | – | 10,400 |
| John Neuman Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 88,000 |
| Jennifer A. Baird Director | Jun 4, 2025 | Option exercise | +2,667 | – | – | 18,000 |
| Jennifer A. Baird Director | May 20, 2025 | Buy | +10,000 | $1.28 | $12.80K | 10,000 |
| Kevin Chung Chief Medical Officer | May 20, 2025 | Buy | +4,500 | $1.25 | $5.63K | 18,185 |
| John Neuman Director | Dec 11, 2024 | Buy | +10,000 | $2.04 | $20.40K | 40,000 |
| Kevin Chung Chief Medical Officer | Nov 18, 2024 | Buy | +4,250 | $1.99 | $8.46K | 13,685 |
| Kevin Chung Chief Medical Officer | Sep 30, 2024 | Buy | +1,000 | $4.26 | $4.26K | 9,435 |
| David A. Green Chief Financial Officer | Aug 30, 2024 | Award | +8,100 | – | – | 10,323 |
| John Neuman Director | Aug 15, 2024 | Buy | +10,000 | $5.24 | $52.40K | 30,000 |
| John Neuman Director | Jun 17, 2024 | Buy | +10,000 | $4.35 | $43.50K | 20,000 |
| John Neuman Director | Jun 14, 2024 | Buy | +10,000 | $3.69 | $36.90K | 10,000 |
| David A. Green Chief Financial Officer | Apr 18, 2024 | Award | +2,223 | – | – | 2,223 |
| Allan Collins Director | Apr 12, 2024 | Award | +37,943 | – | – | 54,343 |
| Bruce M. Rodgers Director | Apr 12, 2024 | Award | +36,537 | – | – | 44,515 |
| Heel Kenneth Van Director | Apr 12, 2024 | Award | +43,564 | – | – | 159,964 |
| Andres Lobo Director | Apr 12, 2024 | Award | +32,322 | – | – | 40,300 |
| Rick Barnett Director | Apr 12, 2024 | Award | +70,264 | – | – | 86,664 |
| David A. Green Chief Financial Officer | Apr 12, 2024 | Award | +752,500 | – | – | 752,500 |
| Richard D. Russell Director | Apr 12, 2024 | Award | +32,322 | – | – | 60,300 |
| Kevin Chung Chief Medical Officer | Nov 29, 2023 | Award | +63,422 | – | – | 210,860 |
| Eric Schlorff Chief Executive Officer, Director | Nov 29, 2023 | Award | +60,248 | – | – | 837,823 |
| Caryl Baron Interim CFO | Nov 29, 2023 | Award | +20,293 | – | – | 139,872 |
| Heel Kenneth Van Director | Nov 22, 2023 | Buy | +100,000 | $0.40 | $40.00K | 116,400 |
| Caryl Baron Interim CFO | Sep 22, 2023 | Other | +15,070 | – | – | 119,579 |
| Caryl Baron Interim CFO | Sep 15, 2023 | Award | +4,110 | – | – | 104,506 |
| Eric Schlorff Chief Executive Officer, Director | Sep 15, 2023 | Award | +41,109 | – | – | 779,862 |
| Kevin Chung Chief Medical Officer | Sep 15, 2023 | Award | +34,257 | – | – | 154,490 |
| Kevin Chung Chief Medical Officer | Aug 31, 2023 | Award | +28,125 | – | – | 113,181 |
| Eric Schlorff Chief Executive Officer, Director | Aug 31, 2023 | Award | +33,750 | – | – | 736,466 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of SeaStar Medical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 151,970 shares on Oct 8, 2026 over the last 90 days.
See a number that looks wrong?